Implementing the Decision-Aid for Lupus (IDEAL Strategy)
NCT03735238 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1895
Last updated 2025-10-10
Summary
The study will attempt to put into practice a shared decision making (SDM) strategy, using an individualized, computerized decision- aid (DA) for Systemic lupus erythematosus (SLE).
Conditions
Interventions
- OTHER
-
SMILE Computerized Decision-Aid
SMILE is a computerized decision-aid designed to give lupus patients information about lupus, treatments for lupus available to them, as well as side effects. This will be administered at every lupus clinic session. Every patient will see the SMILE Computerized Decision-Aid at their index baseline clinic visit.
Sponsors & Collaborators
-
Patient-Centered Outcomes Research Institute
collaborator OTHER -
University of Alabama at Birmingham
lead OTHER
Principal Investigators
-
Jasvinder A Singh, MD, MPH · University of Alabama at Birmingham
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-12-15
- Primary Completion
- 2024-11-15
- Completion
- 2025-06-10
Countries
- United States
Study Locations
More Related Trials
-
A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus
NCT02725515 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Systemic Lupus Erythematosus
NCT00001372 ·Status: RECRUITING
-
Psychoeducational Approach to Improve Health in Lupus
NCT00000417 ·Status: COMPLETED ·Phase: PHASE2
-
PRediction Of Flares In Lupus With autoantibodiEs and Chemokines
NCT04951427 ·Status: UNKNOWN
-
Reducing Disparities in Medication Adherence in SLE
NCT03738826 ·Status: COMPLETED ·Phase: NA
-
Lupus Intervention for Fatigue Trial
NCT02653287 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus
NCT03161483 ·Status: COMPLETED ·Phase: PHASE2
-
An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus
NCT03252587 ·Status: COMPLETED ·Phase: PHASE2
-
Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients
NCT02119156 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
NCT00137969 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus
NCT01283139 ·Status: COMPLETED ·Phase: PHASE2
-
Addressing Disparities in Lupus Care Through an Integrated Care Management Program
NCT03915652 ·Status: COMPLETED ·Phase: NA
-
Multicomponent Strategy to Implement a Clinical Practice Guideline and Improve Health Outcomes in People With SLE
NCT03537638 ·Status: COMPLETED ·Phase: NA
-
Lupus Interval Monitoring to Manage Disease Flare and Enable Treatment Optimization
NCT03142412 ·Status: UNKNOWN
-
Disease Progression and Activity in Patients With Systemic Lupus Erythematosus
NCT00339261 ·Status: COMPLETED
-
Interleukin23 in Systemic Lupus
NCT06713187 ·Status: RECRUITING ·Phase: NA
-
A Model About the Response of Belimumab in SLE
NCT04893161 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Healthy Lifestyle Intervention in Patients with Systemic Lupus Erythematosus: the Living Well with Lupus Study
NCT04431167 ·Status: COMPLETED ·Phase: NA
-
Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE)
NCT00987831 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
NCT03742037 ·Status: COMPLETED ·Phase: PHASE2
-
Intervention to Improve Quality of Life in African American Lupus Patients
NCT01837875 ·Status: COMPLETED ·Phase: NA
-
Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76
NCT01914770 ·Status: COMPLETED
-
Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
NCT01632241 ·Status: COMPLETED ·Phase: PHASE4
-
Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease
NCT01753401 ·Status: COMPLETED ·Phase: PHASE4
-
A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies
NCT01858792 ·Status: COMPLETED